Talaris Therapeutics, Inc.
NASDAQ:TALS
2.72 (USD) • At close October 19, 2023
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2024 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|
| Operating Activities: | |||||
| Net Income
| -73.21 | -73.894 | -47.833 | -22.707 | -18.155 |
| Depreciation & Amortization
| 0.039 | 2.162 | 0.623 | 0.447 | 0.379 |
| Deferred Income Tax
| 0 | 0 | 0.394 | 0.095 | -0.038 |
| Stock Based Compensation
| 6.593 | 11.156 | 3.778 | 1.022 | 0.229 |
| Change In Working Capital
| 0 | 1.097 | 2.315 | 1.614 | -0.085 |
| Accounts Receivables
| 0 | 0 | 0 | 0 | 0 |
| Inventory
| 0 | 0 | 0 | 0 | 0 |
| Accounts Payables
| 2.437 | 1.664 | 1.323 | 0.1 | 0.321 |
| Other Working Capital
| 0 | -0.567 | 0.992 | 1.514 | -0.406 |
| Other Non Cash Items
| 0 | -1.378 | 0.735 | 0.317 | 0.01 |
| Operating Cash Flow
| -77.263 | -60.857 | -39.988 | -19.212 | -17.66 |
| Investing Activities: | |||||
| Investments In Property Plant And Equipment
| -0.009 | -3.043 | -2.437 | -1.286 | -0.562 |
| Acquisitions Net
| 0 | -0.059 | 0.094 | 0 | 0 |
| Purchases Of Investments
| -366.136 | -191.579 | -275.879 | -158.237 | 0 |
| Sales Maturities Of Investments
| 171.84 | 250.293 | 181.929 | 26.224 | 0 |
| Other Investing Activites
| 0 | 0.059 | -0.094 | -0.001 | 0 |
| Investing Cash Flow
| -194.305 | 55.671 | -96.387 | -133.3 | -0.562 |
| Financing Activities: | |||||
| Debt Repayment
| 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued
| 161.352 | 0 | 0 | 0 | 0 |
| Common Stock Repurchased
| 0 | 0 | 0 | 0 | 0 |
| Dividends Paid
| 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities
| -0.004 | 0.242 | 137.4 | 131.123 | 36.204 |
| Financing Cash Flow
| 161.348 | 0 | 0.137 | 131.123 | 36.204 |
| Other Information: | |||||
| Effect Of Forex Changes On Cash
| 0 | 0 | 0 | 0 | -0.001 |
| Net Change In Cash
| -110.22 | -4.944 | 1.025 | -21.389 | 17.981 |
| Cash At End Of Period
| 30.733 | 13.67 | 18.614 | 17.589 | 38.978 |